Saxenda Dose: Starting Dosage, Weekly Escalation and Missed Dose

The Saxenda starting dosage is 0.6 mg once daily for one week. After that the label's Table 1 adds 0.6 mg each week until 3 mg is reached. Each pen holds 6 mg/mL, so every 0.6 mg step is another 0.1 mL.

The first four weeks use 42 mg in total, a little over two 18 mg pens. Saxenda is injected once a day at any time, with or without meals, in the abdomen, thigh or upper arm; the label adds that injection sites should be rotated within the same region. The injection sites guide covers rotation in more detail.

The ladder is the same molecule as Victoza's, pushed further. Victoza stops at 1.8 mg for type 2 diabetes; the Victoza dosage guide explains why that product is not a weight-loss dose. For liraglutide's pharmacology and half-life, see the liraglutide dosage page.

The weekly timetable is the default, not a requirement to push through symptoms. The label allows for slowing it:

• Adults: if an increased dose is not tolerated during escalation, consider delaying the next increase by about one extra week.
• Adolescents: if an increased dose is not tolerated, it may be lowered to the previous level, and escalation may take up to 8 weeks instead of 4.

What the label does not offer adults is a permanent stop below 3 mg. For adults the recommended dose is 3 mg and the lower doses are "for titration only"; if 3 mg cannot be tolerated, the label says to discontinue rather than settle at 2.4 mg. That is a real difference from the weekly drugs, where lower maintenance doses are part of the label. The GLP-1 medications guide compares maintenance rules across products, and the Wegovy dosing schedule shows the weekly semaglutide equivalent.

Because Saxenda is daily, a Saxenda missed dose is a small event as long as the gap stays short. The prescribing information and the patient Medication Guide say the following.

The restart rule is the part that catches people out. Tolerance to nausea fades quickly, so going straight back to 3 mg after a long break is exactly the jump the four-week ladder was designed to avoid. If you have missed several days, the restart plan is a conversation with the prescriber.

Saxenda is labelled for pediatric patients aged 12 and older who have obesity and a body weight above 60 kg. The dose ladder is the same, but three rules differ from the adult label:

• Maintenance: 3 mg daily is recommended, but adolescents who do not tolerate it may have the maintenance dose reduced to 2.4 mg daily.
• Stopping for intolerance: discontinue if 2.4 mg cannot be tolerated.
• Response check: evaluate BMI after 12 weeks on the maintenance dose and discontinue if BMI has not fallen by at least 1% from baseline.

The label's 56-week adolescent trial (251 pubertal patients aged 12 to 17) titrated to 3 mg over 4 to 8 weeks; 82.4% reached 3 mg and for 8.8% the maximum tolerated dose was 2.4 mg. The label also notes that hypoglycemia occurred in adolescents on Saxenda even though none had type 2 diabetes. Saxenda's safety and effectiveness have not been established in pediatric patients with type 2 diabetes.

The Saxenda label is unusual in writing a response test into the dosing section. The stop points are:

• Adults, no response: evaluate body weight 16 weeks after starting; discontinue if at least 4% of baseline weight has not been lost, because meaningful, sustained loss is unlikely with continued treatment.
• Adults, intolerance: discontinue if 3 mg cannot be tolerated.
• Adolescents: less than 1% BMI reduction after 12 weeks on maintenance, or intolerance of 2.4 mg.
• Safety stops: suspected pancreatitis, a sustained increase in resting heart rate, or a serious hypersensitivity reaction. When a pregnancy is recognised, the label says to discontinue.

Note that the 16-week check includes the four escalation weeks, so it falls after roughly 12 weeks at 3 mg. Two recent label changes are worth knowing if you read an older copy: pregnancy was removed from the contraindications in 05/2025 (the pregnancy section still advises stopping once pregnancy is recognised), and the warning on suicidal behaviour and ideation was removed in 02/2026.

The Saxenda injection dose is dialled, not drawn. Each prefilled pen holds 18 mg in 3 mL (6 mg/mL) and the dose selector offers 0.6, 1.2, 1.8, 2.4 and 3 mg. By arithmetic, one pen gives at most six 3 mg doses; each new pen needs a one-time flow check, and a pen in use is discarded 30 days after first use. Cartons hold three or five pens. Unused pens are refrigerated at 2 to 8 °C and never frozen; a pen in use can stay at 15 to 30 °C or in the fridge for those 30 days.

Liraglutide from a vial drawn with an insulin syringe is not Saxenda and is not interchangeable with it. If a prescriber has supplied one, the unit count depends entirely on concentration:

Units on a U-100 syringe = dose in mg ÷ (vial mg ÷ mL of water) × 100

EXAMPLE concentration only: 10 mg mixed with 2 mL gives 5 mg/mL, so 0.6 mg is 12 units, 1.2 mg is 24, 1.8 mg is 36, 2.4 mg is 48 and 3 mg is 60 units. A different concentration changes every figure. Use the liraglutide calculator or the mg to mL and units converter for your own numbers, and the syringe measurement guide for reading the barrel.

All three adult 56-week trials titrated to 3 mg over four weeks alongside a reduced-calorie diet and activity counselling. The label reports these mean results:

These are group averages from supervised trials, and individual results spread widely around them. They are smaller than the averages reported in the weekly semaglutide and tirzepatide trials; the weight loss injections guide and the Zepbound dosing guide cover the alternatives.